New York favoured option for foreign listing of Saudi Aramco

Ikaba Koyi Sharecast | 11 Aug, 2017 17:03 | | |

aramco-valorise-autour-de-1-000-1-500-milliards-de-dollars

New York is likely to be the favoured option for the foreign listing of the state oil giant Saudi Aramco, not London or Hong Kong.

The Big Apple was likely to be the favoured option for the Kingdom's government and Crown Prince Mohammad bin Salman, a senior industry source told Reuters, due to "political considerations" on account of the long-standing relationship between Riyadh and Washington, although financial and commercial factors would also play a role.

"All awaits on the final shareholder decision," the source said.

It was believed that several advisers recommended London for the main listing outside Saudi Arabia, due to concerns that a US flotation would require greater disclosure of sensitive information on Aramco, such as internal estimates of its proven energy reserves and projections on future oil prices.

Nonetheless, Aramco stressed in a statement that no decision had been taken yet on the listing venue beyond the Saudi exchange Tadawul, according to Reuters, and neither the New York or London stock exchange have commented.

With the flotation expected to raise billions of dollars which could be used to help develop other Saudi industries, Hong Kong was also a contender, other sources told Reuters.

The exchanges were fighting to win a part of the flotation on the belief that it would boost their trading volumes and help them win listings from other Gulf States which were also looking to partially privatise their commodity assets.

More news

17 Oct US close: Markets finish higher amid busy earnings season

US markets finished in the green on Tuesday, with the Dow closing just short of the 23,000 mark which it breached for the first time ever earlier in the session, amid a busy third quarter earnings season on Wall Street.

17 Oct Europe close: Stocks slip ahead of US Fed Beige Book

Stocks on the Continent finished slightly lower as investors bid their time ahead of the release of the US central bank's Beige Book on Wednesday, against the backdrop of fresh intra-day records on Wall Street's main benchmarks with the Dow Industrials having climbed above the 23,000 point mark for the first time ever.

17 Oct Buy Spain as political risk is 'overstated' - Credit Suisse

Spanish equities look unusually cheap, said Credit Suisse on Tuesday, as political risk is "overstated" and the country is on track for at least 3% growth, with employment, housing and construction all on a growth tear.

17 Oct London close: Stocks move lower even as Sterling slips

London stocks closed lower on Tuesday even as the pound fell back against the dollar, albeit following a brief pop higher after data showed inflation surged to a five-year high last month, amid somewhat dovish remarks from Bank of England policymakers.

17 Oct Director dealings: Beazley executive director sells after profit warning

Adrian Cox, executive director of risk insurance and reinsurance group Beazley, sold 180,009 shares in the company on Tuesday at the price of 500p per share.

17 Oct Credit Suisse cuts Tate and Lyle's target price, reiterates 'neutral' rating

Ahead of Tate & Lyle's interim results on 2 November, Credit Suisse updated its forecasts and cut its target price to 710p while reiterating its 'neutral' rating.

17 Oct US open: Dow Industrials clambers atop 23,000 mark for first time

The Dow Industrials climbed past the 23,000 points mark for the first time ever, as the third-quarter earnings season got into full swing, and then slipped lower.

17 Oct Higher inflation means benefits pain for households, says IFS

State benefits for roughly 10m UK families will be reduced by £450 a year in real terms after inflation reached its highest level in five years on Tuesday, the Institute for Fiscal Studies calculated.

17 Oct FTSE 250 movers: Virgin Money gains on update, Workspace boosted by JPM note

London's FTSE 250 was down 0.4% to 20,140.65 in afternoon trade on Tuesday.

17 Oct Johnson and Johnson raises full year targets after strong third quarter

Healthcare giant Johnson and Johnson posted higher than expected profits for the three months to 30 September thanks to increased demand for its new cancer drugs and the additional revenue afforded to the group from its June acquisition of Swiss biotech company Actelion.